Search This Blog

Tuesday, January 9, 2024

Fanigate Widens: Atlanta Trump Prosecutor's Alleged DA Lover Met White House Counsel Pre Indictment

 Fulton County District Attorney Fani Willis hired her secret lover to serve as special prosecutor in the Georgia racketeering case against Donald Trump and 18 other defendants, according to a Monday filing on behalf of Mike Roman, a defendant who led election day operations for the 2020 Trump campaign: 

“[T]he district attorney and the special prosecutor have been engaged in an improper, clandestine personal relationship during the pendency of this case, which has resulted in the special prosecutor, and, in turn, the district attorney, profiting significantly from this prosecution at the expense of the taxpayers."

The prosecutor is Nathan Wade, a private attorney in the midst of a divorce who "has little to no experience trying felony cases, much less complex RICO actions," according to the 127-page filing which seeks to have the charges against Roman dropped and both Willis and Wade disqualified from further participation in the case.  

Fani Willis hired Nathan Wade at a steep premium to what she was paying other prosecutors in her office, the filing alleges (Atlanta News First)

According to the complaint, Wade has raked in at least $653,000 and upwards of $1 million for handling the high-profile case. By virtue of their relationship, that pile of taxpayer money benefits Willis, as they've traveled together to Florida, the Caribbean and Napa Valley, California, adding that Wade has also bought tickets for the pair to travel on Norwegian and Royal Caribbean cruise ships. 

In addition to his $250 hourly rate, Wade has also billed Fulton County for thousands of dollars in air travel and hotel stays, according to invoices attached to the filing. He categorized them as interview and research trips. 

The Trump filing also alleges that Willis contracted with Wade without proper approval, as such a move requires a vote by the Fulton County Board of Commissioners. Roman's lawyer, Ashleigh Merchant tells the Wall Street Journal her search of board meeting minutes found no indication his appointment was ever discussed, much less voted upon.

Attorney Ashleigh Merchant filed the motion seeking Willis and Wade's disqualification and the dropping of charges against Mike Roman

The timing of the transaction was rich: Wade filed for divorce the very day after his first contract with Willis began. The divorce is still pending, and Wade managed to have the proceedings sealed -- for now. Merchant is asking for them to be unsealed.

Monday's filing sums up the shadiness of the dealings nicely: 

On the day before Wade filed for divorce, [Willis] entered into an agreement to pay Wade far above what any other prosecutor in her office was being paid, and she hid this agreement from Fulton County, despite Wade being the single biggest expenditure in her office for professional service contractors for both 2022 and 2023.   

...

Wade is being paid hundreds of thousands of dollars to prosecute this case on her behalf. In turn, Wade is taking Willis on, and paying for vacations across the world with money he is being paid by the Fulton County taxpayers and authorized solely by Willis.

“It’s a bad look and it’s potentially criminal—again, assuming everything is true,” former Georgia prosecutor Chris Timmons tells the Journal. However, while Willis's procurement of Wade's services may have been illegal, Timmons doubts it would affect the indictment. 

Willis has yet to comment on the accusations, and a spokesman says a response will come "via a filing with the court." The filing contains plenty of documentation about Wade's hiring and billings, but no evidence of the romantic relationship, beyond citing "sources close" to the couple.   

Four defendants have pleaded guilty in the Fulton County case that alleges a conspiracy to interfere with the 2020 presidential election. Roman faces seven charges, including conspiracy to commit forgery, conspiracy to file false documents and racketeering. 

And just when you thought it all couldn't get any shadier, there's also this gem in the heap of exhibits attached to the filing...

As the Daily Caller notes;

After his appointment as a special prosecutor, Wade met with officials of the White House Counsel’s Office on May 23 and Nov. 18, 2022, during Willis’ investigation of Trump and several months prior to his indictment, according to billing records included in a motion to disqualify Wade from the case.

In both cases, Wade billed the district attorney’s office $2,000 for eight hours of work regarding his meetings with the White House Counsel’s Office. The names of the officials he met with are unknown, and it is unclear whether he met with Dana Remus or Stuart Delery, Biden’s two White House counsels during that period.

So - the fullness of time has unsurprisingly revealed this to be yet another Democrat hatchet job against Donald J. Trump.

https://www.zerohedge.com/political/georgia-trump-prosecutor-accused-secret-disqualifying-romance-da-fani-willis

SEC Approves Bitcoin Spot ETF

 SEC Chair Gary Gensler - having issued his pre-emptive warning at just how terrifyingly dangerous cryptos are - proudly proclaimed the approval of Spot Bitcoin ETFs on X:

There are more than a dozen applications pending with the SEC, according to Decrypt (and the implication of Gensler's post is that they are all apporved):

iShares Bitcoin Trust (BlackRock)

Jane Street Capital, JP Morgan Securities, Macquarie Capital, and Virtu Americas have all been named as authorized participants for BlackRock's Bitcoin ETF.

VanEck Bitcoin Trust (VanEck)

Jane Street Capital, Virtu Americas LLC, and ABN AMRO Clearing have all signed agreements to act as authorized participants.

Franklin Bitcoin ETF (Franklin Templeton)

Jane Street Capital and Virtu Americas have each signed authorized participant agreements with Templeton.

Fidelity Wise Origin Bitcoin Trust (Fidelity)

Fidelity names Jane Street Capital, JP Morgan Securities, Macquarie Capital, and Virtu Americas LLC as authorized participants for its Bitcoin ETF.

Valkyrie Bitcoin Fund (Valkyrie)

Jane Street Capital and Cantor Fitzgerald & Co. have signed authorized participant agreements with Valkyrie.

WisdomTree Bitcoin Fund (WisdomTree)

The latest filing from WisdomTree shows lists Jane Street Capital, Macquarie Capital, and Virtu Americas as authorized participants.

Invesco Galaxy Bitcoin Fund (Invesco, Galaxy Digital)

JP Morgan Securities, Virtu Americas, Jane Street Capital, and Marex Capital Markets Inc. have all signed authorized participant agreements with Inveso.

Bitwise Bitcoin ETF (Bitwise)

Jane Street Capital, Macquarie Capital, and Virtu Americas have signed on to be authorized participants for Bitwise's Bitcoin ETF.

Grayscale Bitcoin Trust (Grayscale)

Jane Street Capital, Virtu Americas, Macquarie Capital, and ABN AMRO Clearing have all signed authorized participant agreements with Grayscale.

ARK 21Shares Bitcoin ETF (ARK Invest, 21Shares)

Jane Street Capital, Macquarie Capital, and Virtu Americas will be authorized participants for ARK's Bitcoin ETF.

Bitcoin spiked up to $48,000 on the headline... and right back down...

Testing its highest since March 2022...

Interestingly, while BTC is fading, ETH is ramping higher (playing catch up to recent relative weakness) in anticipation of a Spot Ethereum ETF...

Meanwhile, in the Senate...

Developing...

https://www.zerohedge.com/crypto/sec-approves-bitcoin-spot-etf

C4: 2024 Priorities and Extended Cash Runway, at JP Morgan

 Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials

Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30%

Unaudited Cash, Cash Equivalents and Marketable Securities Totaling Approximately $330 million as of January 5, 2024, Combined with Cost Savings from Restructured Operations, Results in Cash Runway into 2027

Company to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11

C4T will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 am PST (12:00 pm EST). A live webcast will be available under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

https://www.globenewswire.com/news-release/2024/01/09/2806663/0/en/C4-Therapeutics-Announces-2024-Priorities-and-Extended-Cash-Runway-to-Advance-Portfolio-of-Targeted-Protein-Degradation-Medicines.html

NASA delays astronaut moon landing to 2026 amid spacecraft 'challenges'

 NASA on Tuesday added more delays to its Artemis moon program, scheduling for 2026 its first astronaut lunar landing in half a century while spacecraft from Elon Musk's SpaceX, Lockheed Martin and other contractors face development challenges.

The U.S. space agency's first two Artemis missions involving astronauts were each pushed back nearly a year in delays designed "to give the Artemis teams more time to work through the challenges," NASA administrator Bill Nelson told reporters in a news conference.

Artemis 3, the first crewed moon landing under the program using SpaceX's Starship, is now scheduled for September 2026, previously planned for late 2025, NASA said.

The precursor to that moon landing mission, Artemis 2, was also delayed, now planned for September 2025, NASA said. Artemis 2 involves four astronauts flying the Lockheed-built Orion capsule around the moon and back. Reuters reported on Monday the moon mission delays were imminent.

The new schedule "acknowledges the very real development challenges that have been experienced by our industry partners," said Amit Kshatriya, head of NASA's moon and Mars exploration strategy.

NASA astronauts' journey to the moon will be a relay among multiple spacecraft in space, initially launching off Earth aboard Orion then transferring in space to SpaceX's Starship system to go to and from the lunar surface.

Issues and investigations around Orion's heat shield, the shell that protects astronauts from the heat of re-entering Earth's atmosphere, and the spacecraft's batteries and electrical system are among the reasons for the delays, Kshatriya said.

Orion first launched to space in 2022 without people aboard in NASA's Artemis 1 mission, which marked the first flight of the agency's powerful Space Launch System rocket.

SpaceX, though it has been test-launching Starship from Texas, still faces a lengthy to-do list before the craft lands astronauts on the moon. It must demonstrate it can dock and refuel to other "tanker" Starships in orbit, a process inherent to its design in transporting astronauts anywhere beyond Earth's orbit.

Kshatriya called those feats "extremely challenging."

Jessica Jensen, SpaceX's vice president of customer operations and integration who was also on the call with reporters, downplayed the fuel transfer challenges. SpaceX has demonstrated similar docking events in orbit with its Crew Dragon capsule, Jensen said.

Jensen said roughly 10 Starship launches will be required to fill up the "tanker" Starship that will act as an orbital fuel station. The lander Starship will top off there before putting humans on the moon.

https://www.marketscreener.com/quote/stock/ORION-S-A-16970740/news/NASA-delays-astronaut-moon-landing-to-2026-amid-spacecraft-challenges-45708486/

Resmed: JP Morgan raises the target price from USD 160 to USD 195.

  maintains its overweight recommendation

https://www.marketscreener.com/quote/stock/RESMED-INC-14259/

BioNTech expects 2024 revenues of about $3.3 billion

 COVID-19 vaccine maker BioNTech on Tuesday forecast total company revenues of about 3 billion euros ($3.28 billion)for 2024, as it works to scale up its oncology business with product launches in the coming years.

The company, which developed the Western world's most widely used COVID-19 shot with U.S. partner Pfizer, with which it shares costs, said it ended 2023 with about 17.5 billion euros in cash, cash equivalents and security investments according to preliminary, unaudited figures.

BioNTech is targeting a strong financial position and significant interest income generation in the current year, it said in a statement.

"Currently, late-stage trials are ongoing in multiple oncology indications, and we plan to have ten or more potentially registrational trials in our pipeline by the end of 2024," BioNTech co-founder and chief executive Ugur Sahin said.

The company aims to scale the business for commercial readiness in oncology in multiple countries by the end of 2025 and expects its first oncology launches from 2026 onwards.

BioNTech said it would provide detailed full-year 2024 guidance alongside its 2023 financial results on March 20.

https://www.marketscreener.com/quote/stock/BIONTECH-SE-66771992/news/BioNTech-expects-2024-revenues-of-about-3-3-billion-45704935/

Apellis: Strong prelims

 

  • Approximately $114 million in preliminary fourth quarter SYFOVRE® revenue as strong launch continues
  • Approximately $24 million in preliminary fourth quarter EMPAVELI® revenue